Edition:
United Kingdom

Celyad SA (CYAD.BR)

CYAD.BR on Brussels Stock Exchange

37.68EUR
19 Jan 2018
Change (% chg)

€-0.30 (-0.79%)
Prev Close
€37.98
Open
€38.10
Day's High
€38.10
Day's Low
€36.92
Volume
29,025
Avg. Vol
63,609
52-wk High
€56.48
52-wk Low
€18.89

Select another date:

Fri, Nov 17 2017

BRIEF-Celyad ends Q3 with EUR 40 million in cash, confirms previous guidance

* CONFIRMS ITS PREVIOUS GUIDANCE THROUGH TO THE FIRST HALF 2019 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Celyad reports first complete response in relapsed refractory AML patient in THINK trial ‍​

* REPORTS A FIRST COMPLETE RESPONSE IN A RELAPSED REFRACTORY AML PATIENT IN THE THINK TRIAL ‍​

BRIEF-Celyad SA files for mixed shelf offering of up to $250 mln

* Celyad SA files for mixed shelf offering of up to $250 million - SEC filing ‍​ Source text: [http://bit.ly/2xBg9Sn] Further company coverage:

BRIEF-Celyad H1 operating loss narrows to 13.7 million euros

* H1 OPERATING LOSS EUR 13.7 MILLION VERSUS LOSS OF EUR 17.2 MILLION YEAR AGO

BRIEF-BioLife Solutions executes supply agreement with Celyad for CryoStor

* Biolife Solutions executes supply agreement with Celyad for CryoStor use in natural killer receptor based t-cell (nkr-t) platform targeting solid tumors and blood cancers

BRIEF-Celyad announces initiation of the SHRINK trial

* SHRINK TRIAL IS THIRD CLINICAL TRIAL WITH ITS LEAD PRODUCT CANDIDATE CYAD-01 (CAR-T NKG2D), TARGETING METASTATIC COLORECTAL PATIENTS

Select another date: